Zylem Biosciences

Zylem Biosciences is a privately held biotechnology company based in Chicago, Illinois, United States. The company is developing targeted medicines that modulate oxidative damage in human cells, a mechanism implicated in cancer, cardiovascular disease, ocular conditions, dermatological conditions, and aging. Its core technology platform is a portfolio of patented Metabolic Redox Modulators (MRMs), which are tunable mimics of natural molecules modeled on high-density lipoproteins (HDLs) that target the scavenger receptor SR-B1. According to the company, SR-B1 was previously considered a known but undruggable target; MRMs are designed to tightly bind SR-B1 and thereby modulate oxidative stress and inflammation. The company's stated mission is to increase healthy human lifespan by modulating oxidative stress and inflammation, which it describes as key causes of disease and aging. Zylem's pipeline is initially focused on targeted oncology, where its MRMs are designed to induce what the company calls "Metabolic Checkmate" by regulating three hallmarks of cancer simultaneously: enhancing immune destruction, reducing tumor-promoting inflammation, and inducing cancer cell death by enhancing oxidative stress. Beyond oncology, the company is pursuing applications in cardiovascular disease, ocular disease, and dermatological conditions. Zylem has outlined a three-stage long-term roadmap. The first stage applies its patented MRM technology to cancer and cardiovascular disease. The second stage involves developing anti-aging MRMs for skin rejuvenation in commercial products through a partnership with a major worldwide cosmetics company. The third stage focuses on developing preventative medicines to prevent inflammation and oxidative damage. The science underlying Zylem's platform was developed over approximately 15 years of research led by Dr. Shad Thaxton's laboratory at Northwestern University. More than $20 million in funding from the National Institutes of Health (NIH), the Department of Defense, and the Howard Hughes Foundation has been dedicated to the MRM platform technology, according to the company. The founding team includes scientists, academic experts, and biotechnology industry leaders; the patented technology exclusive to Zylem originated from work by Dr. Thaxton and Dr. McMahon in the Thaxton Laboratory at Northwestern University, with Dr. Gordon, a hematologic malignancies expert, playing a key role in facilitating MRMs for aggressive lymphoma. Zylem Biosciences operates as a private company and maintains its official web presence at zylembio.com. The company publishes educational content on topics such as the role of HDL in cancer, the use of large language models in biotechnology, and radiosensitizers as a potential 510(k) pathway to FDA approval.

Zylem Biosciences is a biotechnology company based in Chicago, Illinois, United States. Its scientific foundation was laid over approximately 15 years of research conducted in the laboratory of Dr. Shad Thaxton at Northwestern University. That work produced the patented Metabolic Redox Modulator (MRM) technology platform, which is exclusively licensed to Zylem. According to the company, more than $20 million in funding from the National Institutes of Health (NIH), the Department of Defense, and the Howard Hughes Foundation was dedicated to developing the MRM platform technology. The MRM platform consists of tunable mimics of natural molecules modeled on high-density lipoproteins (HDLs) that target the scavenger receptor SR-B1. The company states that SR-B1 was previously a known but undruggable target, and that MRMs tightly bind SR-B1 to modulate oxidative stress and inflammation. This mechanism is intended to enable potent killing of cancer cells and regulation of cellular damage in heart disease and dermatological conditions. The founding team of Zylem includes scientists, academic experts, and biotechnology industry leaders. The patented technology originated from work by Dr. Thaxton and Dr. McMahon in the Thaxton Laboratory at Northwestern University. Dr. Gordon, described as a world-renowned expert in hematologic malignancies and a longtime collaborator, played a key role in facilitating the application of MRMs to aggressive lymphoma. Zylem has articulated a three-stage long-term vision and roadmap. The first stage is the application of its patented MRM technology to cancer and cardiovascular disease. The second stage involves developing anti-aging MRMs for skin rejuvenation in commercial products through a partnership with a major worldwide cosmetics company. The third stage is the development of preventative medicines to prevent inflammation and oxidative damage. The company's pipeline is initially focused on targeted oncology. Its MRMs are designed to induce what Zylem calls "Metabolic Checkmate" by regulating three hallmarks of cancer in one shot: enhancing immune destruction, reducing tumor-promoting inflammation, and inducing cancer cell death by enhancing oxidative stress. The company also describes development programs in ocular and cardiovascular disease, as well as anti-aging treatments for mitochondrial restoration. As of its 2024 website, Zylem Biosciences operates as a private company and publishes educational articles on topics including the role of HDL in cancer, the use of large language models in biotechnology, and radiosensitizers as a potential 510(k) pathway to FDA approval.

• Research underlying the MRM platform conducted over approximately 15 years in Dr. Shad Thaxton's lab at Northwestern University.

• Over $20 million in funding from NIH, Department of Defense, and Howard Hughes Foundation dedicated to the MRM platform technology.

• Zylem Biosciences founded to commercialize the patented MRM technology.

• Company website published with pipeline and science overview, copyright 2024.

A preclinical-stage biotechnology company developing a novel class of metabolic redox modulators for oncology, cardiovascular, ocular and anti-aging applications.

• Metabolic Redox Modulators (MRMs)

  Tunable mimics of natural molecules modeled on high-density lipoproteins (HDLs) that target SR-B1, designed to modulate oxidative stress and inflammation.

• Targeted oncology therapeutics

  MRMs designed to induce 'Metabolic Checkmate' by regulating three hallmarks of cancer: enhancing immune destruction, reducing tumor-promoting inflammation, and inducing cancer cell death.

• Cardiovascular disease therapeutics

  MRMs for regulation of cellular damage in heart disease.

• Ocular disease therapeutics

  MRMs for ocular disease applications.

• Anti-aging skin rejuvenation treatments

  Anti-aging MRMs for skin rejuvenation in commercial products through partnership with a major worldwide cosmetics company.

1. 1Home - Zylem Bioscienceszylembio.com
2. 2About Us - Zylem Bioscienceszylembio.com
3. 3Zylem Biosciences - Wikidatawikidata.org